Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
Brainstorm Cell Therapeutics (BCLI) Announces Pricing of $7.5 Million Registered Direct Offering
-
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
-
BrainStorm Cell Therapeutics to Participate in the Maxim Group Healthcare Virtual Conference
-
Brainstorm Cell Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT
-
Maxim Group Upgrades Brainstorm Cell Therapeutics (BCLI) to Buy
-
Maxim Group Downgrades Brainstorm Cell Therapeutics (BCLI) to Hold
-
BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 Share
-
Brainstorm Cell Therapeutics (BCLI) PT Raised to $8 at Maxim Group
-
Maxim Group Reiterates Buy Rating and $6 PT on BrainStorm Cell Therapeutics (BCLI) Following New CMO Appointment
-
Brainstorm Cell Therapeutics (BCLI) Bullish View Reiterated at Maxim Group Following New Data Presentation
-
Brainstorm Cell (BCLI) ALS Trial Results 'Robust' - Maxim Group
-
Maxim Positive on BrainStorm Cell Therapeutics (BCLI) into Upcoming NurOwn Phase 2 Data in ALS; Affirms at 'Buy'
-
Brainstorm Cell Therapeutics (BCLI) PT Cut to $5 at Maxim Group; 'Buy' Maintained
-
Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report
-
Brainstorm Cell Therapeutics (BCLI) Completes Nurown Phase 2 Enrollment, Continues Executing Business Plan - Maxim
-
Brainstorm Cell Therapeutics (BCLI) Bullish Stance Reiterated at Maxim Group Following ALS Study Data
-
ALS Data Shows Neuralstem (CUR) Approach is 'Risky' - Maxim Group
-
Brainstorm Cell Therapeutics (BCLI) Bullish Stance Reiterated at Maxim Group Following Capital Raise
-
Brainstorm Cell Therapeutics (BCLI) Enters 2.5M Common Warrant Exercise Agreement

